The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.

The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.

A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global anatomic pathology market is projected to grow from $93.03 billion in 2024 to $224.44 billion by 2033 at a CAGR of 10.28%, driven by rising cancer burden, aging populations, and AI-powered digital pathology adoption. North America leads with over 41% market share, supported by advanced healthcare infrastructure and precision oncology investments. Disease diagnostics account for 74.42% of revenue, with cancer diagnostics representing 60% of biopsy applications globally.

The global breast cancer imaging market is expected to grow at a CAGR of 7.7% from 2025 to 2033, driven by rising breast cancer incidence, technological advancements in imaging modalities like tomosynthesis and CESM, and increased government healthcare initiatives for early detection and screening.

The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulatory requirements and high manufacturing costs.

AI-driven clinical intelligence is transforming medical imaging, with point-of-care diagnostics projected to reach $70.92 billion by 2032. The CMS ACCESS Model launching in July 2026 will reward outcome-based care, driving adoption of software-defined imaging platforms. Key players including VentriPoint Diagnostics, Butterfly Network, Hyperfine, Hologic, and GE HealthCare are advancing portable, AI-powered diagnostic solutions that deliver hospital-grade precision at the bedside, reducing facility overhead while improving patient outcomes.

Law firm Brodsky & Smith has initiated investigations into four major merger transactions, examining whether the boards of Diamond Hill Investment Group, Synchronoss Technologies, Forge Global Holdings, and Hologic breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders.

The inaugural National Women's Health Summit will take place in Toronto on March 24-25, 2026, bringing together health researchers, clinicians, and advocates to discuss critical women's health issues and potential innovations.

A national women's health summit will be held in Toronto on March 24-25, 2026, bringing together researchers, clinicians, and health advocates to discuss critical women's health issues and drive meaningful change.

Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies undergoing significant corporate transactions, including mergers and acquisitions.

The global breast cancer screening tests market is projected to grow from $4.75 billion in 2025 to $8.77 billion by 2034, with a 7.04% CAGR. Driven by increasing cancer awareness, technological advances in screening, and government initiatives, the market will see significant expansion in imaging and blood marker tests.